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Abstract
Background: Dual antiplatelet therapy using acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great
importance following coronary stenting. However, the variable platelet inhibitory effectiveness compromises the
antithrombotic advantages provided by dual antiplatelet therapy. The aim of this single-center prospective study
was to reduce the low response incidence of dual antiplatelet therapy with ASA and clopidogrel according to a
prespecified therapy algorithm.
Methods: Platelet function testing using whole blood aggregometry (Chronolog 590) was performed 48 hours
following coronary stenting (for either acute coronary syndromes or stable coronary artery disease) on 504 patients.
The antiplatelet therapy included a loading dose of 600 mg clopidogrel and 500 mg ASA, followed by 75 mg
clopidogrel and 100 mg ASA once daily. Clopidogrel low responders (CLR: >5 ohm; adenosine diphosphate (ADP)
5 μM) and/or ASA low responders (ALR: >0 ohm; arachidonic acid 10 μM) were treated according to a structured
therapy plan: in the case of CLR, the maintenance + dose was doubled (repeated loading dose followed by
150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used.
ALR was treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification did
not take effect sufficiently. In addition, ADP receptor antagonist 2-methylthioadenosine 5’-monophosphate
triethylammonium salt (MeSAMP) testing and ASA incubation were performed to rule out either a platelet
ADP-receptor defect or an ASA pharmacokinetic resistance.
Results: Of the total cohort of 504 patients, we detected 30.8% clopidogrel low-responders and 19.4% aspirin low-
responders. For ALR, with a dose adjustment of 300 mg ASA daily, 94.6% of ALR were effectively treated and the
residual 5.4% by administration of daily dosages of 500 mg ASA. This means that after modification of the ASA
maintenance dose, all initial ALRs had an adequate antiplatelet response.
The results for clopidogrel revealed that 69% of the CLR were treated effectively by increasing the clopidogrel dose
to 150 mg daily. When prasugrel was not available or contraindicated, 12.7% of the remaining low responders
showed an adequate result after being switched to ticlopidine. Consequently, by applying the therapy algorithm,
we were able to reduce the CLR prevalence by 86.6%. On including prasugrel in the therapy plan, we were finally
able to eliminate thienopyridine low response. In addition, no ADP receptor defect was found in this study as a
potential reason for CLR.
We identified the following factors associated with both CLR and ALR status: acute coronary syndromes, positive
troponin values as well as diabetes mellitus and elevated HbA1C values and a higher platelet count. Furthermore,
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reproduction in any medium, provided the original work is properly cited.our data revealed for CLR elevated C-reactive protein values and a high PREDICT-score (including an age >65 years,
acute coronary syndrome, diabetes mellitus, renal failure, and reduced left ventricular function) as risk factors. The
following factors correlated with the risk of ASA low response: patients with elevated hemoglobin, serum
creatinine and C-reactive protein values. In addition, medication with nitrates reduced the risk of being CLR. As also
holds true for CLR, we found the PREDICT-score to be correlated to the risk of being ALR. However, by far the
strongest risk factor for CLR or ALR was the fact of dual resistance.
Conclusion: Following a structured therapy plan based on a “test and treat” strategy, the prevalence of clopidogrel
or aspirin low response can be significantly reduced and the risk of inadequate dual antiplatelet therapy
minimized.
Trial Registration: NCT01212302 (Clinicaltrials.gov)
Background
Dual antiplatelet therapy with acetylsalicylic acid (ASA,
aspirin) and thienopyridines is of great importance for
the prevention of ischemic events in patients with ather-
othrombotic disease. ASA has been shown to reduce
early mortality in patients with acute coronary syn-
dromes (ACS) by about one quarter and the risk of
stroke or non-fatal reinfarction by about one half [1].
The platelet inhibitory effect of ASA is caused by block-
ing the thromboxane mediated aggregation pathway. In
addition to ASA, the thienopyridines ticlopidine, clopi-
dogrel and prasugrel inhibit ADP-mediated platelet acti-
vation by blocking the P2Y12 adenosine diphosphate
platelet receptor and reduce thrombotic and ischemic
events [2,3].
Despite the proven benefits of dual antiplatelet ther-
apy, complications did arise and it became apparent that
the platelet inhibitory effect of clopidogrel and ASA was
lower in 5 to 30% of the patients [4,5]. The mechanisms
leading to poor response (low- or hypo-response, resis-
tance) of clopidogrel are multifactoral, including lack of
compliance and such clinical factors as diabetes mellitus
[6]. Further data suggest that cytochrome polymorphism
(that is, CYP 2C19) contribute to clopidogrel low
response [7-9]. Clopidogrel low-responder (CLR) and
ASA low-responder (ALR) bear a significantly higher
risk of cardiovascular complications and especially of
stent thrombosis [10-12]. A recent meta-analysis
revealed that ASA resistance occurred on average in
28% of patients with a wide range from 0% to 57%
depending on the methods used of varying time points,
different cut-off values and variable concentrations of
the stimulating agents [12]. Furthermore, ASA dosing
differed in most studies. When taking a more specific
approach, the incidence of ASA resistance in studies
using arachidonic acid stimulation was approximately
six percent [4]. The therapeutic options for clopidogrel
and/or aspirin low-responders requiring dual anti-
thrombotic therapy are still undetermined. Data suggest
improving platelet inhibition in low-responders to
clopidogrel by increasing the loading dose [13-15], and
applying a higher maintenance dose [16-19] or by
switching to alternative thienopyridine treatment (ticlo-
pidine, prasugrel) [16,20,21]. Further studies suggest that
the incidence of ASA low response is dose dependent
[22], thus an option in treating ALR is to increase the
ASA dose.
The aim of our study was to identify CLR and ALR in
order to optimize antiplatelet therapy by using platelet
function testing. We examined the hypothesis that a
standardized therapeutic algorithm can reduce the
prevalence of CLR and ALR.
Methods
Study population
Patients with either stable coronary artery disease (CAD)
or acute coronary syndromes (ACS) following percuta-
neous coronary intervention (PCI) were enrolled in this
prospective, single-center interventional study. They
were treated initially with an ASA loading dose of 500
m g ,f o l l o w e db y1 0 0m gA S Ap e rd a ya n das t a r t i n g
dose of 600 mg clopidogrel-hydrogensulfate, followed by
a daily dose of 75 mg. Exclusion criteria were an abnor-
mal platelet count in patients, severe liver disorders,
current gastrointestinal disorders, a current infection,
congestive heart failure or a known bleeding disorder as
well as treatment with bivalirudin or glycoprotein
IIb/IIIa antagonists within the last seven days. The
present study was approved by the institutional ethics
committee and complies with the Declaration of
Helsinki. Written informed consent was obtained from
all study participants before entering the study.
Platelet function testing
The platelet function test used to monitor the antiplate-
let effectiveness of clopidogrel and ASA was whole
blood aggregometry (WBA, impedance aggregometry
(IPA)) (Model 590, Chrono-log Corporation, Havertown,
PA, USA) and was done >48 h following coronary stent-
ing (but not more than 72 h later). Measurements were
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Citrate blood (500 μl) was diluted 1:1 with 0.9% sodium
chloride and preincubated for 10 minutes at 37°C in a
polycarbonate cuvette. After a stable baseline had been
established, the agonists (Chrono-Par, Chrono-log
Corporation, Havertown, PA, USA), either adenosine
diphosphate (ADP) with a final concentration of 5 μMo r
arachidonic acid (AA, final concentration 0.5 mmol/L)
were added and the impedance (Ω) was registered after
six minutes.
We prospectively defined low response in accordance
to previous studies by setting a cut-off point for
ADP-induced impedance exceeding 5 Ω for clopidogrel
low response (CLR) [16,23] and AA-induced impe-
dance values exceeding 0 Ω were defined as ASA low
response (ALR) [24,25]. The results measured with the
Chrono-log 590 aggregometer were reproducible with
a variability <10%.
Kidney function was assessed using the estimated
glomerular filtration rate (eGFR), calculated from serum
creatinine using the Cockcroft-Gault method. Diabetes
mellitus was defined as having a physician’s diagnosis in
the patient’s history or the intake of any antidiabetic
drug or insulin. Troponin positive status was defined
when troponin T values exceeded 0.1 ng/mL. The
PREDICT-score was calculated as previously shown,
including such clinical variables as ACS, diabetes
mellitus, renal failure, age >65 years and reduced left
ventricular function [26].
Bleeding complications were recorded during the hos-
pital stay or by interview when further platelet function
tests had to be scheduled. Hemorrhagic complications
were defined as major bleedings in the case of intracra-
nial haemorrhage, a drop in the haemoglobin level of
3 g/dl or bleeding at the access site that required inter-
vention or the need of blood transfusions.
Study protocol
In the case of low response the ASA and/or clopidogrel
treatment was modified in accordance to a structured
therapy plan (Figures 1, 2 and 3).
The prespecified therapy plan for CLR 75 mg included
the following options: as a first step, standard dose clo-
pidogrel low responders were given another loading
dose (600 mg), followed by a doubled clopidogrel main-
t e n a n c ed o s e( 1 5 0m gd a i l y ) .If the measurements still
did not reveal an adequate effect, the next step, as long
as prasugrel was not available, was to change the ADP-
inhibitory medication to ticlopidine 250 mg twice daily
(after a loading dose of 500 mg was given) and again
the platelet inhibitory effect was evaluated 48 h later by
aggregometry. For CLR and ticlopidine low responders
(TLRs), a defect of the ADP-receptor was evaluated
by the selective P2Y12 ADP receptor antagonist
2-methylthioadenosine 5’-monophosphate triethylammo-
nium salt (MeSAMP, Sigma-Aldrich, Munich, Germany)
to disclose a defect at the level of the P2Y12 ADP
receptor (Figure 1). When prasugrel was not available
(up until April 2009) or contraindicated, CLR and TLR
patients were kept on long-term treatment with high
clopidogrel dosage and follow-up measurements were
scheduled regularly. On including prasugrel, the therapy
plan was modified as follows (Figure 2): Clopidogrel
Figure 1 Study plan optimizing clopidogrel treatment without
prasugrel. (Prasugrel not available or contraindicated). Platelet
function assay (if treatment ineffective, next step), Tx indicates
treatment; high clopidogrel dose of 150 mg daily, ticlopidine 2 ×
250 mg daily.
Figure 2 Study plan optimizing clopidogrel treatment
including prasugrel. (Prasugrel available and not contraindicated).
Platelet function assay (if treatment ineffective, next step), high
clopidogrel dose of 150 mg daily, high prasugrel dose of 20 mg
daily.
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(60 mg loading, 10 mg prasugrel daily) and the measure-
ments were repeated (>48 h). In the case of prasugrel
low response (PLR), the dose was increased to 20 mg
prasugrel daily (once again IPA-testing was carried out
>48 h later). However, in the case of increased thieno-
pyridine treatment dosages, the time period was limited
to four weeks following bare metal stenting (BMS) and
six months when drug eluting stents (DES) had been
used.
The therapy algorithm for ALRs included as a first
step the application of another loading dose of 500 mg
ASA, followed by 300 mg ASA daily (Figure 3). If these
patients showed an adequate inhibitory effect in
IPA testing (<1 ohm of AA induced platelet aggregation)
48 hours later, they were defined as ASA “high mainte-
nance dose” responders. On detecting an insufficient
inhibitory effect, the ASA dose was further increased to
500 mg ASA daily ("maximum dose ASA” response if
adequate IPA results existed 48 h later). To rule out
pharmacokinetic ASA resistance, the blood samples
were incubated with 500 mg ASA ("ASA test”). Patients
without a sufficient platelet inhibitory effect on a dose
of 500 mg ASA daily were defined as “ASA definite low
responder”.
Statistical analysis
Univariate analysis was performed with X
2 testing for
categorical variables and a t-test (Mann-Whitney U test
for non-normal distributions) for continuous variables.
The odds ratios for the association between predictors
(independent variables) and ASA or clopidogrel low
response status were expressed in corresponding two-
sided 95% confidence intervals (CIs) and P-values.
Sample size calculation for the present study was based
on the assumption that the incidence of clopidogrel low
response was at least 20% and ASA low response 10%.
Choosing a power of 97.5% and a two-sided value of 0.05,
an overall sample size was required of at least 400
patients. To compensate for a possible loss of follow-up,
we aimed for inclusion of 500 patients.
All statistical calculations were performed using SAS,
version 9.1 (SAS Institute Inc., Cary, NC, USA) and
SPSS 18 (SPSS, Chicago, IL, USA).
Results
Clinical and demographic data
A total of 504 patients treated with PCI participated in
the study. The prevalence of dual responders to antipla-
telet therapy with ASA and clopidogrel was 58.3%,
isolated CLR 22.3%, isolated ALR 10.9% and the rate of
dual low response was 8.5% (Figure 4).
The mean age was 64.3 ± 11.7 years, 30.5% were
females and the majority of patients (67.8%) had an
acute coronary syndrome (ACS). The patients took mul-
tiple co-medications (number of drugs 7.5 +/- 2.4) with
a high rate of ACE-inhibitors (87.1%), ß-blockers
(88.0%), statins (79.1%) and proton pump inhibitors
(PPIs; 42.3%). Clinical and baseline characteristics of the
s t u d yp o p u l a t i o na r es h o w ni nT a b l e s1a n d2 .D u r i n g
the hospital stay and in the case of follow-up visits
due to repeated platelet function measurements, we did
not observe any significant differences between the
treatment groups in regard to hemorrhagic complica-
tions (major bleeding events) and the need for blood
transfusions.
Figure 3 Study plan optimizing ASA treatment. Platelet function
assay (if treatment ineffective, next step), ASA (acetylsalicylic acid,
aspirin) 100 mg daily.
58,3
5,6
22,3 10,9 8,5
94,4
0 0
05 0 1 0 0
Following
Modification
Initial Low
Responder
Prevalence
Responder CLR ALR Dual LR
Figure 4 Results of the entire study group.P r e v a l e n c eo fA L R ,
CLR and Dual LR before and after modification according to the
therapy algorithm (without prasugrel) Percentage of dual responder
(Responder), clopidogrel low responder (CLR), ASA low responder
(ALR) and dual low responder (Dual LR) before and after
optimization of antiplatelet therapy. Note: By applying the therapy
algorithm (without prasugrel), the low responder rate can be
reduced absolute by 36.1% (relative -86.6%) and including prasugrel
low response was eliminated.
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modification
We identified 30.8% (n = 155) of the patients to be CLR.
By increasing the clopidogrel maintenance dose from
75 mg to 150 mg daily, the majority (69.0%) of the
CLRs were treated effectively. When prasugrel was not
available or contraindicated, patients without an ade-
quate response despite the high clopidogrel maintenance
dose were switched to ticlopidine. By doing this, 12.7%
of the high dose CLR attained a sufficient inhibition of
ADP-induced platelet aggregation. When the patients
still had an inadequate response (5.6% of the whole
study group) they were kept on a high clopidogrel main-
tenance dose and long-term follow-up measurements
were scheduled (Figure 5). On this dosage, 3 out of 13
definite CLR patients gained an adequate response in
the following weeks.
When applying the treatment plan and including pra-
sugrel we made the following findings: of the CLR on a
high maintenance dose, 92% were effectively treated
with prasugrel 10 mg daily. The prasugrel dose had to
be adjusted to 20 mg daily in only three patients and
Table 1 Baseline Demographic and Clinical Characteristics Comparing Clopidogrel Low Responder and Responder
Variable Clopidogrel Low-Responder Clopidogrel Responder OR (95% CI) p-Value
No. (%) 155 (30.8) 349 (69.2)
Female gender (%) 54 (34.8) 101 (28.9) 1.31 (0.88-1.97) n.s. (0.21)
Age (years) 64.5 (11.5) 64.4 (11.7) n.s. (0.93)
BMI (kg/m
2) 28.06 (5.00) 27.81 (4.20) n.s. (0.56)
EF (%) 52.82 (12.50) 54.23 (10.50) n.s. (0.19)
Acute coronary syndrome 122 (78.7) 214 (61.3) 2.33 (1.50-3.63) <0.001
Arterial hypertension 124 (80.0) 282 (80.8) 0.95 (0.59-1.53) n.s. (0.90)
Diabetes mellitus 74 (47.7) 124 (35.5) 1.66 (1.13-2.43) 0.01
Lipid disorder 95 (61.3) 211 (60.5) 1.04 (0.70-1.53) n.s. (0.92)
Cigarette smoking 68 (43.9) 157 (45.0) 0.96 (0.65-1.40) n.s. (0.85)
Familial CAD disposition 33 (21.3) 63 (18.1) 1.23 (0.77-1.97) n.s. (0.39)
ASA 100 mg 153 (98.7) 349 (100) 0.09 (0.01-1.84) n.s. (0.09)
Beta-Blockers 138 (89.0) 302 (86.5) 1.26 (0.70-2.28) n.s. (0.47)
Nitrates 24 (15.5) 72 (20.6) 0.70 (0.42-1.17) n.s. (0.22)
Calcium-channel blockers 49 (31.6) 101 (28.9) 1.14 (0.75-1.71) n.s. (0.60)
ACE Inhibitors 133 (85.8) 301 (86.2) 0.96 (0.56-1.66) n.s. (0.89)
Diuretics 73 (47.1) 138 (39.5) 1.36 (0.93-1.99) n.s. (0.12)
Statins 125 (80.6) 269 (77.1) 1.24 (0.77-1.98) n.s. (0.41)
Proton pump inhibitors 62 (40.0) 151 (43.3) 0.87 (0.59-1.29) n.s. (0.56)
Number of drugs 7.69 (2.30) 7.36 (2.30) n.s. (0.14)
WBC (×10
9/l) 9.22 (4.17) 8.71 (6.10) n.s. (0.34)
Hemoglobin (g/dl) 14.12 (1.60) 14.28 (1.90) n.s. (0.36)
Platelet count (×10
9/l) 230.34 (69.62) 212.00 (87.97) 0.02
Troponin positive (%) 35 (22.6) 37 (10.6) 2.46 (1.48-4.09) <0.001
CK max (U/l) 428.85 (1246.60) 391.61 (783.70) n.s. (0.68)
Total cholesterol (mg/dl) 203.70 (57.30) 204.37 (50.10) n.s. (0.89)
CRP (mg/l) 11.47 (20.70) 7.34 (15.40) 0.01
HbA1C (%) 6.71 (1.60) 6.42 (1.30) 0.03
D-dimer (mg/l) 0.57 (0.50) 0.57 (0.40) n.s. (1.00)
Serum creatinine (mg/dl) 1.06 (0.60) 1.04 (0.30) n.s. (0.62)
GFR (MDRD) (ml/min) 76.34 (24.20) 75.87 (20.90) n.s. (0.82)
PREDICT-score 3.38 (2.0) 2.48 (1.90) <0.001
ASA low-response 44 (28.4) 31 (8.9) 4.07 (2.45-6.76) <0.001
Data presented are mean ± SD and count (no.) or percentage (%). Calculation of p-values was done by unpaired t-test or chi-square test, comparing
low-responder versus responder. OR = odds ratio; CI = confidence interval; n.s. = not significant.
BMI = body mass index, EF = ejection fraction, CAD = coronary artery disease, ASA = acetylsalicylic acid (aspirin), ACE = angiotensin-converting enzyme,
WBC = white blood cells, CK = creatine kinase, CRP = C-reactive protein, HbA1C = hemoglobin A1c, GFR = glomerular filtration rate.
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effect (Figure 6).
ASA low response and effect of therapy modification
Measurements of ASA effectiveness were taken of 403
patients. The rate of ASA low responsiveness was 19.4%
(78 patients). Loss of follow-up data in 22 patients was
caused by a transfer to coronary artery bypass grafts
(CABG), by the patients having been discharged or pro-
ven to be ineligible for treatment in accordance with the
study plan (for example gastrointestinal reasons). Of the
ASA low responders who were optimized according to
the therapy algorithm, 94.6% (n = 53) were effectively
treated by using a 300 mg ASA maintenance dose. By
increasing the ASA dose to 500 mg daily all remaining
ALRs finally became ASA responders (Figure 7). In con-
clusion, guided by platelet function test, ASA resistance
was eliminated after individual dosage adjustments were
made according to the treatment scheme.
Identifying risk factors for CLR or ALR
The analysis of the demographic and clinical data of
CLR revealed that the following factors influenced the
incidence of clopidogrel low response (Table 1): as is
Table 2 Baseline Demographic and Clinical Characteristics Comparing ASA Low Responder and Responder
Variable ASA Low-Responder ASA Responder OR (95% CI) p-Value
No. (%) 78 (19.4) 325 (80.6)
Female gender (%) 19 (24.4) 101 (31.1) 0.71 (0.40-1.26) n.s. (0.27)
Age (years) 63.80 (12.90) 64.30 (11.70) n.s. (0.74)
BMI (kg/m
2) 28.17 (5.10) 27.81 (4.30) n.s. (0.52)
EF (%) 52.78 (13.90) 54.35 (11.10) n.s. (0.29)
Acute coronary syndrome 61 (78.2) 211 (64.9) 1.94 (1.08-3.48) 0.03
Arterial hypertension 62 (79.5) 258 (79.4) 1.01 (0.54-1.86) n.s. (1.0)
Diabetes mellitus 38 (48.7) 113 (34.8) 1.78 (1.08-2.94) 0.03
Lipid disorder 44 (56.4) 193 (59.4) 0.89 (0.54-1.46) n.s. (0.70)
Cigarette smoking 33 (42.3) 148 (45.5) 0.88 (0.53-1.45) n.s. (0.62)
Familial CAD disposition 10 (12.8) 68 (20.9) 0.56 (0.27-1.14) n.s. (0.11)
Beta-Blockers 71 (91.0) 279 (85.8) 1.67 (0.72-3.86) n.s. (0.27)
Nitrates 8 (10.3) 71 (21.8) 0.41 (0.19-0.89) 0.03
Calcium-channel blockers 25 (32.0) 90 (27.7) 1.23 (0.72-2.10) n.s. (0.49)
ACE Inhibitors 67 (85.9) 276 (84.9) 1.08 (0.53-2.19) n.s. (1.0)
Diuretics 39 (50.0) 124 (38.2) 1.62 (0.99-2.67) n.s. (0.07)
Statins 58 (74.4) 257 (79.1) 0.77 (0.43-1.36) n.s. (0.36)
Proton pump inhibitors 29 (37.2) 147 (45.2) 0.72 (0.43-1.19) n.s. (0.21)
Number of drugs (n ± SD) 7.50 (2.80) 7.48 (2.20) 1.67 (0.72-3.86) n.s. (0.95)
WBC (×10
9/l) 9.80 (4.10) 8.70 (5.40) 0.09
Hemoglobin (g/dl) 14.71 (2.40) 14.07 (1.50) 0.003
Platelet count (×10
9/l) 250.33 (10.22) 205.80 (63.69) <0.001
Troponin positive (%) 34 (43.6) 53 (16.3) 3.97 (2.32-6.78) <0.001
CK max (U/l) 478.15 (1508.40) 529.77 (638.70) n.s. (0.64)
Total cholesterol (mg/dl) 205.63 (60.60) 202.14 (51.30) n.s. (0.60)
CRP (mg/l) 12.26 (21.40) 7.22 (15.40) 0.02
HbA1C (%) 6.88 (1.70) 6.41 (1.30) 0.007
D-dimer (mg/l) 0.78 (0.60) 1.02 (2.70) n.s. (0.44)
Serum creatinine (mg/dl) 1.14 (0.80) 1.02 (0.30) 0.03
GFR (MDRD) (ml/min) 81.50 (59.70) 78.16 (22.30) n.s. (0.42)
PREDICT score 3.39 (2.20) 2.55 (1.80) <0.001
Clopidogrel low-response 44 (56.4) 74 (22.8) 4.39 (2.62-7.36) <0.001
Data presented are mean ± SD and count (no.) or percentage (%). Calculation of p-values was done by unpaired t-test or chi-square test, comparing
low-responder versus responder. OR = odds ratio; CI = confidence interval; n.s. = not significant.
ASA = acetylsalicylic acid (aspirin), BMI = body mass index, EF = ejection fraction, CAD = coronary artery disease, ACE = angiotensin-converting enzyme,
WBC = white blood cells, CK = creatine kinase, CRP = C-reactive protein, HbA1C = hemoglobin A1c, GFR = glomerular filtration rate.
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text positive troponin values as well, were associated
with CLR. The incidence of diabetes mellitus and ele-
vated HbA1C values were more frequently detected in
CLR. Other significantly elevated laboratory values were
the platelet count and C-reactive protein. We identified
the PREDICT- score to be a strong and significant mar-
ker for the risk of being CLR (P < 0.001). But by far the
strongest risk factor for CLR is an ASA low response
status (OR 4.07 (2.45 to 6.76).
The following factors increased the risk of ASA low
response (Table 2): Patients with acute coronary
syndromes ran a significantly higher risk of being ALR
(OR 1.94 (1.08 to 3.48)). Accordingly, a positive tropo-
nin status was a strong predictor for ALR (OR 3.97
(2.32 to 6.78)). Other clinical factors related to ALR
were diabetes mellitus (OR 1.78 (1.08 to 2.94)) and ele-
vated HbA1C values (P = 0.007). Patients without nitrate
medication ran an increased risk of being ALR, and the
same held true for elevated hemoglobin, platelet count
and serum creatinine values. An interesting finding
was that in the group of ALR, C-reactive protein values
as a marker of inflammation were significantly elevated
(P = 0.02). As is the case with CLR on calculating the
PREDICT-score, a strong correlation existed between a
high PREDICT-score and ALR. The strongest factor for
ALR, however, was the existence of CLR (OR 4.39 (2.62
to 7.36)).
Double low response
Out of the total study group we found 43 patients
(8.5%) to be dual low responders (ALR and CLR). As is
true for either ALR or CLR, risk factors for dual low
response were a high PREDICT-score (P = 0.002), acute
coronary syndrome (P = 0.006), patients with positive
troponin values (p < 0.001) and elevated creatine kinase
values (P = 0.02) (Additional File 1. Supplement
Table 1). In addition we detected more patients with
dual low response when no nitrate medication was given
(P = 0.02). Furthermore, risk factors for dual low
response were significantly elevated serum creatinine
(P = 0.02) and C-reactive protein values (P = 0.006).
21,2
3,9
5,6
30,8 69,2
Clopidogrel Responder Clopidogrel Low Responder
High Clopidogrel Dose Ticlopidine
Definite Low Responder
(249) (111) 
Figure 5 Results of clopidogrel low-response (CLR) following
therapy modification without prasugrel. The left section of the
figure shows the prevalence in % (numbers) of clopidogrel
responder and clopidogrel low responder (CLR). In the right section
are the results after therapy modification according to the therapy
algorithm for CLR. Treatment options used: clopidogrel responder
(75 mg daily), high clopidogrel dose (150 mg daily), ticlopidine
(250 mg twice daily).
20,8
7,7
2,1
0
69,2 30,8
Clopidogrel Responder Clopidogrel Low Responder
High Clopidogrel Dose Prasugrel 10 mg/d
Prasugrel 20 mg/d Definite Low Reponder
(100) (44) 
Figure 6 Results of clopidogrel low-response (CLR) following
therapy modification including prasugrel. The left section of the
figure shows the prevalence in % (numbers) of clopidogrel
responder and clopidogrel low responder (CLR). In the right section
are the results after therapy modification according to the therapy
algorithm for CLR including prasugrel. Clopidogrel responder
were treated with 75 mg daily and the high clopidogrel dose was
150 mg daily. Definite low responder were low responder to either
clopidogrel high dose or prasugrel high dose.
1,05
0
80,6 19,4 18,35
ASA 100 mg Responder ASA 100 mg Low Responder
ASA 300 mg Responder ASA 500 mg Responder
Definite ALR
 (325)  (78) 
Figure 7 Results of ASA low response (ALR) before and after
therapy modification. The left section of the figure shows the
prevalence in % (numbers) of ASA responder and ASA low
responder (ALR). In the right section are the results after therapy
adjustment of ASA dose according to the therapy algorithm
for ALR.
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pharmacodynamic problem
In high dose CLR, MeSAMP testing was carried out and
did not reveal any case of ADP-receptor problem in our
study. Furthermore, we detected that all ALR showed an
adequate inhibitory effect of AA-induced platelet aggre-
gation when the blood samples were incubated in vitro
with ASA (ASA-test).
Discussion
The present study demonstrates that dual antiplatelet
therapy using ASA and clopidogrel can be significantly
improved when using a tailored “test and treat”
approach. Our data revealed that following a structured
therapy plan based on platelet function testing, ASA low
r e s p o n s ec a nb eo v e r c o m eb ys t e p w i s ei n c r e a s i n gt h e
ASA maintenance dose. Also, the prevalence of clopido-
grel hypo-/low-response can be significantly decreased
by 86.6% by dose escalation or switch to ticlopidine.
When prasugrel was included in the therapy algorithm,
thienopyridine resistance was able to be eliminated.
Antiplatelet agents provide the cornerstone of medical
treatment in cardiovascular medicine. Despite the pro-
ven benefit of preventing stent thrombosis following
PCI and stent implantation, dual antiplatelet therapy
with ASA and thienopyridines (ticlopidine or clopido-
grel) is limited by the variability in the antiplatelet
response [4,5]. Data have linked therapeutic failure
(resistance, low- or hypo-responsiveness) to antiplatelet
therapy to an increased risk of cardiovascular complica-
tions including stent thrombosis [10]. Compared to clo-
pidogrel resistance, ASA resistance has so far received
little attention in interventional cardiology. But as is
true of clopidogrel, the response to ASA treatment is
variable and resistance to ASA is linked to an increase
in the major adverse cardiac event (MACE) rate [12]. In
our study we found 30.8% of the patients to be CLR and
19.4% to be ALR. Of these patients 8.5% were dual low
responders. With the need for more effective and sus-
tained antiplatelet therapy to reduce cardiovascular mor-
bidity, it is worthwhile to evaluate the effect of dual
antiplatelet therapy using medications, ASA and thieno-
pyridines, in order to optimize the effectiveness of the
platelet inhibitory response. With the use of the pre-
sented therapeutic algorithm we were able to overcome
resistance to ASA and CLR either by 86.6% (without
prasugrel) or even to overcome it when prasugrel was
included. Our structured therapy plan for optimizing
dual antiplatelet therapy does not depend on a specific
platelet test. We chose whole blood platelet testing
because of several advantages it provided: compared to
other assays, the method used is inexpensive, easy to
perform and requires only 10 minutes [27]. The multi-
ple electrode aggregometry (MEA) test system uses a
similar technique [4,27]. However, other methods to
monitor the response of antiplatelet medication can also
be used to guide the therapy modifications according to
the therapy algorithm presented here.
Improving CLR
What are the options on how to treat clopidogrel low
responders? Data suggest improving platelet inhibition
in low-responders to clopidogrel by using alternative
treatment strategies, including either an increase in the
loading dose [13-15] or the use of a higher maintenance
dose [16-19], or by switching to alternative thienopyri-
dine treatment (ticlopidine, prasugrel) [16,20,21]. In
addition, new platelet inhibitors are an alternative, such
as ticagrelor or thrombin receptor antagonists and these
agents will be introduced in the near future [28,29].
Data demonstrated that adjusting the clopidogrel load-
ing dose according to platelet function testing translates
to a significantly improved short-term outcome follow-
ing PCI [30]. The RELOAD study reveals that a new
clopidogrel loading dose in patients treated long term
with 75 mg clopidogrel daily, improves platelet inhibi-
tion and this in turn reduces low response [31].
Regarding the maintenance therapy, studies have
demonstrated that 150 mg clopidogrel lead to a greater
inhibition of platelet aggregation than a 75 mg daily
dose [17,18]. The ACC Practice Guidelines of 2005
recommend (Class IIb) increasing the dose of clopido-
grel to 150 mg per day if less than 50% inhibition of
platelet aggregation is apparent [32]. The CURRENT-
OASIS-7 study evaluated the effect of 600 mg loading
dosage and then doubling the maintenance dose
(150 mg) of clopidogrel in ACS patients as compared to
standard therapy (300 mg, followed by 75 mg) [19]. In
this study, all patients on a higher clopidogrel dosage
had lower MACE rates. However, with this unselected
approach involving a higher clopidogrel dosage irrespec-
tive of the antiplatelet effect, the study group observed a
higher rate of major bleeding events according to the
“CURRENT” definitions [19]. Using a higher clopidogrel
dose only in risk patients (CLR) would (theoretically)
avoid this unnecessary overtreatment. Further studies
will have to prove if this approach of platelet function
testing will lead to an improvement of antiplatelet
therapy, thus providing better clinical results [33]. Given
the options to overcome clopidogrel resistance, we opti-
mized the antiplatelet therapy according to a pre-
defined therapy plan guided by platelet function testing.
In a first step we combined both: In the case of CLR, an
additional loading dose of 600 mg clopidogrel was given
and the maintenance dose was increased to 150 mg
daily. On this dosage, the majority of patients (69%) was
able to obtain an adequate inhibitory response to
ADP-induced aggregation.
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medication to other thienopyridines. As long as contra-
indications for prasugrel apply (history of stroke, age
>75 years, <65 kg) or prasugrel was not available, ticlo-
pidine was used in patients with high dose CLR. We,
and others, have shown that ticlopidine with a partly
different metabolism is an alternative in treating CLR
patients [16,20]. With the use of ticlopidine instead of
clopidogrel, our study demonstrates that 12.7% of the
remaining CLR can be effectively treated despite the use
of high dose clopidogrel. The reason for this could be
the partially different metabolism of ticlopidine as com-
pared to clopidogrel, with CYP2B6 and CYP2C19 con-
tributing mainly to the activation of ticlopidine [2].
However, it has to be kept in mind that the inferior
safety profile of ticlopidine involves the risk of such side
effects as neutropenia in roughly 2.4% of patients [5].
We, therefore, preferred using clopidogrel in higher
maintenance dosages instead of ticlopidine.
When the third generation thienopyridine prasugrel
was included in the therapy algorithm, 92% of the high
dose CLRs were treated effectively with a standard dose
of prasugrel and the remaining 8% showed an adequate
platelet inhibitory response on 20 mg prasugrel. Our
study revealed that when including prasugrel, we were
able to eliminate thienopyridine resistance. Compared to
clopidogrel, prasugrel has the advantage of providing a
less variable, but more effective and faster antiplatelet
response due to a more effective metabolism [2,29]. In
contrast to the two-step metabolism of clopidogrel, pra-
sugrel is transformed by a single CYP-dependent oxida-
tive step into its active metabolite [2]. As a result
prasugrel achieves a 10 times higher level of the active
metabolite than clopidogrel [2,29].
Improving ALR
Compared to clopidogrel, the data on the clinical impact
of ASA low response in patients treated with dual anti-
platelet medication are limited as most studies focus pri-
marily on identifying and treating clopidogrel resistance.
Nevertheless, a meta-analysis revealed that patients who
are resistant to ASA are at a greater risk of clinically
important cardiovascular morbidity than patients who
are sensitive to ASA [12]. The ALR prevalence depends
on the test method and agonist used, as well as on the
clinical setting (high proportion of patients with ACS in
our study (67.8%)), ASA dose and cut-off definition
[4,5]. As is true of clopidogrel treatment, the influence
of non-compliance can attribute to the prevalence of
ASA low response [4]. However, as our measurements
were done early after PCI during the hospital stay, we
do not assume that a high proportion of non compli-
ance as a cause for ALR or CLR. In our study the preva-
lence of ALR was 19.4%. As we were able to eliminate
ASA low response by stepwise increasing the ASA dose,
other investigators found similar results: In the ASPECT
study with stable CAD, the ALR rate was 1.6% on
81 mg ASA daily, but it was no longer detected when
using 325 mg ASA [22]. Similar findings were published
by another working group, with an ALR prevalence of 2%
in 700 patients, which was caused by non-compliance or
underdosing [34]. Recently the randomized CURRENT-
OASIS-7 study has revealed that the efficacy of ASA to
reduce the MACE rate as well as safety (bleeding events)
did not differ between high dose (300 to 325 mg) and low
dose ASA (75 to 100 mg) [19]. However, it must also be
taken into consideration that in other studies an increase
of ASA doses was associated with an increase in adverse
events, such as haemorrhages [3-5].
Dual resistance of antiplatelet agents
A special group to be considered are patients with dual
antiplatelet resistance as these patients bear the greatest
risk of major adverse events, such as stent thrombosis.
In accordance with previous studies we identified a pre-
v a l e n c eo f8 . 5 %t ob ed u a ll o wr e s p o n d e r s .A na n a l y s i s
of the RECLOSE trial cohort showed a prevalence of 6%
with dual resistance to ASA and clopidogrel [35]. This
dual non-responsiveness was an independent risk factor
and led to markedly higher rates of DES thrombosis
(11.1%) as compared to isolated ASA (2.3%) or clopido-
grel non-responsiveness (2.2%) [35]. Other data revealed
a prevalence of 10.4% dual low response and suggest a
high cardiovascular risk after PCI for these patients with
the need for intensified antiplatelet therapy and follow-
up [23]. As a consequence not only CLR should be
identified to determine the patients’ risk, but ALR is
relevant to the clinical outcome as well.
A single approach focussing on just one option to
overcome resistance to antiplatelet drugs has a limited
potential [36]. Therefore, a structured stepwise therapy
algorithm to individualize antiplatelet therapy is prefer-
able. This is a superior option compared to intensifying
the antiplatelet therapy for all patients regardless of the
degree of platelet inhibition as was done in the CURR-
R E N T - O A S I S - 7s t u d ya st h i si n v o l v e st h er i s ko f
increased adverse bleeding events [19].
Factors influencing low response
In accordance with other studies we identified risk mar-
kers for ALR and CLR. These clinical and demographic
characteristics are mainly comorbidities and concomi-
tant medication [29]. Analysis of the present study
revealed that ACS and elevated troponin values were
strong risk factors for both CLR and ALR. It is known
that ACS patients are at risk due to an increased resi-
dual platelet activity in clopidogrel and ASA-treated
patients as compared to those with a stable coronary
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Page 9 of 12artery disease [26,37]. Especially patients with ACS
might therefore benefit from an alternative or intensified
antiplatelet regimen as we have shown in our study.
Other known risk factors for CLR and ALR, which we
detected, were diabetes mellitus and in this context ele-
vated HbA1C values [26,38]. Interestingly, we found that
C-reactive protein as a marker of inflammation as well
as platelet count was significantly elevated in CLR and
ALR in our study. Furthermore, the data of the present
study suggest that concomitant medication with nitrates
decreases the risk of ALR. In contrast to other data, we
did not find an association with CLR status in regard to
the BMI or co-medication with proton pump inhibitors
and calcium antagonists [29]. In summary, when taking
all the characteristics into consideration (Tables 1
and 2), the most important risk for low response proved
to be a low response to ASA or clopidogrel. The value
of the PREDICT-score was confirmed (ACS, reduced
LV-function, diabetes mellitus, creatinine >1.5 mg/dL,
age >65 years) [26]. Therefore, if platelet function assays
are not available, the use of the PREDICT-score can be
used to identify risk patients. However, it is important
to note that even if it is worthwhile to identify such risk
factors for low response as demographic and clinical
variables or in genotyping patients (CYP2C19*2 poly-
morphism), analysis of the EXCELSIOR-study revealed
only a limited predictive value for this and moreover,
this analysis suggests that platelet function analysis is
much more useful [37].
The reasons for resistance to antiplatelet medication
with ASA and clopidogrel are clinical, cellular and
genetic factors [6,29]. One potential mechanism which
causes a diminished response to thienopyridine medica-
tion is an ADP receptor defect. Therefore we ruled out
in the case of definite CLR by MeSAMP testing (specific
ADP receptor antagonist) an ADP receptor defect as a
cause of clopidogrel resistance. Regarding ASA treat-
ment, we found all ALR to have a pharmacokinetic
resistance as in vitro incubation with ASA revealed in
all ALR patients an adequate platelet inhibitory effect.
Limitations
Our observational, non-randomized study suggests that
antiplatelet therapy can be significantly improved. The
cut-off values and the method used have limitations as
no large scale clinical trials have yet prospectively linked
the measurements to adverse clinical outcomes. In this
context, an approach to define cut-off values for differ-
ent platelet function assays was recently presented [39].
Prospective randomized trials are needed to prove the
clinical benefits of adapting the dosing of clopidogrel or
switching to alternative compounds in high-risk patients
with impaired antiplatelet effectiveness according to the
result of platelet function assays. Future studies will
have to further evaluate if the strategy to improve bio-
chemical response leads to significantly improved
MACE rates without causing an increased risk of
bleeding.
Conclusions
Following a structured therapy plan based on a “test and
treat” strategy, the prevalence of clopidogrel or aspirin
low response can be significantly reduced and the risk
of inadequate dual antiplatelet therapy minimized. Thus,
an individual tailored therapy can significantly improve
the effect of antiplatelet treatment in a majority of
patients after coronary stenting and eliminate resistance
to antiplatelet therapy.
Additional material
Additional file 1: Supplement table. Baseline demographic and clinical
characteristics of clopidogrel and ASA treated patients compared to dual
low responder.
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